[4] In 2018, Edward Rebar became the senior vice president and chief technology officer of Sangamo.

The FDA granted Sangamo fast track designation for SB-525, a gene therapy candidate for haemophilia A.

In its partnership with Pfizer in 2017,[6] Sangamo uses Bioverativ in hemoglobinopathies such as beta thalassemia and sickle cell disease.

[7] In February 2019, medical scientists, working with Sangamo Therapeutics, announced the first ever "in body" human gene editing therapy to permanently alter DNA - in a patient with Hunter syndrome.

[8] As of February 2019[update] clinical trials by Sangamo involving gene editing using zinc finger nuclease were ongoing.